Anixa Biosciences, Inc.

NASDAQ:ANIX

Biotechnology

Healthcare
$2.71 +3.72%

+$0.10 today

Market cap
$94.21M
Beta
0.60
P/E (TTM)
-9.3
EPS (TTM)
-$0.30
52W Low $2.32High $5.46

Volume 0.29M

Average 0.12M

ANIX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Anixa Biosciences, Inc.NASDAQ: ANIX

Gross Profit · Q2 FY2026 · quarter ended Apr 2026

Gross profit remains negative

Q2 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$9K.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$2.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$0— QoQ
Last fiscal yearOct 2025
-$36K— YoY
LTMApr 2026
-$9K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(36K) USD
Year-over-year change
—

Gross Profit vs competitors

How ANIX compares with its peers on the latest reported figures

  • ANIX's LTM Apr 2026 gross profit of -$9K is the 6th highest of the 10 companies compared; the peer median is $0.
ANIX Competitors Peer median
Gross Profit for ANIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$64.58M +289.3%—52.1%
SPROSpero Therapeutics, Inc.LTM Mar 2026$54.77M +162.7%+7.1%100.0%
SEERSeer, Inc.LTM Mar 2026$7.26M +61.1%+70.5%48.3%
IRDOpus Genetics, Inc.LTM Mar 2026$5.95M +1.3%-29.1%49.6%
ACTUActuate Therapeutics IncLTM Mar 2026$0 ———
ANIXAnixa Biosciences, Inc.LTM Apr 2026-$9K ———
ENTXEntera Bio Ltd.LTM Mar 2026-$15K -266.7%——
HURATuHURA Biosciences, Inc.LTM Mar 2026-$23.47K +63.1%——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$46K -4.5%——
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$2.24M -69.6%-81.5%—
Peer median (excluding ANIX) $0+31.2%-11.0%50.9%

Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue512K0210K00
Cost of Revenue385K0161K036K
Gross Profit127K049K0(36K)
Gross Margin24.8%—23.3%——
Research & Development6.19M6.7M4.77M6.4M5.07M
Selling, General & Admin7.07M7.17M6.29M7.44M6.63M
Operating Expenses13.26M13.88M11.06M13.83M11.67M
Depreciation & Amortization59.86K42K46K37K36K
EBITDA(13.08M)(13.73M)(9.88M)(12.66M)(10.99M)
EBITDA Margin-2554.9%—-4706.7%——
Operating Income(13.14M)(13.88M)(11.01M)(13.83M)(11.7M)
Operating Margin-2565.6%—-5243.3%——
Interest Income2.32K104K1.08M1.13M673K
Interest Expense322104K000
Other Income / Expenses7.77K104K1.08M1.13M673K
Income Before Tax(13.13M)(13.77M)(9.93M)(12.7M)(11.03M)
Pre-Tax Margin-2564.0%—-4728.6%——
Income Tax Expense00000
Net Income(12.95M)(13.6M)(9.81M)(12.55M)(10.93M)
Net Margin-2528.6%—-4671.9%——
EPS (Basic)(0.45)(0.45)(0.32)(0.39)(0.34)
EPS (Diluted)(0.45)(0.45)(0.32)(0.39)(0.34)
Weighted Avg Shares28.58M30.37M30.98M31.9M32.45M
Weighted Avg Shares (Diluted)28.58M30.37M30.98M31.9M32.45M

Anixa Biosciences, Inc.

NASDAQ:ANIX

Intrinsic Alpha fair value

Locked

Current Price

$2.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.